Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 in PD-L1+ Relapsed/Metastatic Cervical Cancer
NCT04886700Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of PBI-1308 in Cervical Cancer (CC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
PBI-1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04886700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886700.